Liu Yang

Dr. Liu Yang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
CQChun-Mei Qian
Chun-Mei Qian
LYLiu Yang
Liu Yang
YWYi-Ying Wang
Yi-Ying Wang
ZWZiliang Wang
Ziliang Wang
ZXZi-Hang Xu
Zi-Hang Xu
XWXiao-Yu Wang
Xiao-Yu Wang

6 October 2025 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
XXXiaoyan Xu
Xiaoyan Xu
SYShasha Yu
Shasha Yu
WQWei Qu
Wei Qu
YCYuexia Chen
Yuexia Chen
LYLiu Yang
Liu Yang
Mammary adenoid cystic carcinoma (AdCC) is a rare subtype of invasive breast cancer. Due to its low incidence, the clinicopathological features of mammary AdCC remain incompletely understood. This study aimed to investigate the clinicopathological and molecular characteristics, therapeutic regimens, and prognostic outcomes associated with different subtypes of mammary AdCC. A total of 25 archived specimens of mammary AdCC were collected from the pathology departments of Nanchang People’s Hospital and Zhengzhou People’s Hospital between January 2013 and December 2024. Histomorphological evaluation, immunohistochemical (IHC) analysis, and molecular testing were performed to evaluate the clinicopathological features and prognostic outcomes. Fisher’s exact test was used to analyze the relationship between HER2 status and clinicopathological features. All 25 patients were female, with a mean age of 57.04 years. The tumors manifested as solitary solid nodules, ranging in maximum diameter from 1 to 4.5 cm. Histologically, the tumors were classified as classic adenoid cystic carcinoma (C-AdCC) (21/25), solid-basaloid AdCC (SB-AdCC) (2/25) and AdCC with high-grade transformation (2/25), with Nottingham grade II being the most common (18/25). Immunohistochemical (IHC) analysis demonstrated that most cases exhibited a triple-negative phenotype, characterized by ER-negative (21/25), PR-negative (25/25), and HER2 negativity (IHC score of 0, 1+, or 2 + with no amplification detected by FISH) (25/25). HER2-low expression (IHC score of 1+/2 + with FISH-confirmed non-amplification) was observed in 11 cases (11/25). Neuroendocrine markers were negative in all cases. MYB gene abnormalities, including break-parts or fusion, were identified in 14/25 cases. A statistically significant positive correlation (P < 0.05) was observed between HER2-low expression and MYB gene abnormalities. Axillary lymph node metastasis was observed in 2/25 patients. Following treatment, which included various surgical modalities with or without neoadjuvant chemotherapy, and a follow-up period of 6–136 months, 21 patients remained alive without recurrence or metastasis, 1 patient died at 60 months, and 3 patients were lost to follow-up. These findings support the classification of mammary AdCC as a distinct triple-negative breast cancer (TNBC), with MYB gene abnormalities showing a positive correlation with HER2 status. Notably, mammary AdCC should not be indiscriminately categorized as low-grade TNBC. Precise pathological subtyping of AdCC is critical for guiding clinical management.

30 March 2026 in Pathology - Research and Practice
Verified
Journal Article
Closed access
XXXiaoyan Xu
Xiaoyan Xu
YZYaozhong Zhang
Yaozhong Zhang
HFHuijuan Fang
Huijuan Fang
CLChuan Li
Chuan Li
XXXianwei Xu
Xianwei Xu
LYLiu Yang
Liu Yang

31 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
XSXin Shu
Xin Shu
FWFan Wang
Fan Wang
TZTiancheng Zhao
Tiancheng Zhao
YZYun Zhang
Yun Zhang
YZYao Zhou
Yao Zhou
LDLibin Deng
Libin Deng
Background: Conventional histopathological assessment of residual cancer burden (RCB) following neoadjuvant therapy for breast cancer relies on manual visual evaluation, lacking objective quantification of spatial interactions among tumor, necrosis, and lymphocyte compartments. This limits prognostic accuracy and impedes personalized treatment stratification. Methods: We developed an explainable AI framework to segment three tissue compartments from H&E patches and constructed 11 spatial pathological features. This two-center study included 347 post-neoadjuvant patients (182 development, 165 external validation) plus 843 TCGA-BRCA cases for exploratory external validation. VGG-16, ResNet-50, and ViT-Base were evaluated; multiple instance learning identified target regions for feature construction. Six machine learning models with LASSO-selected features were interpreted via SHAP and Grad-CAM, with TCGA-BRCA serving as an exploratory external cohort. Results: VGG-16 achieved optimal segmentation (all AUCs > 0.90). In the external validation set, XGBoost achieved AUCs of 0.781 for Task 1 (RCB-0 vs. RCB-1+2+3) and 0.896 for Task 2 (RCB-0+1 vs. RCB-2+3). For Task 3 (RCB-0+1+2 vs. RCB-3), the model achieved an AUC of 1.000, with complete separation between groups. SHAP analysis revealed that the Necrotic Tumor Mixed Cluster (T+N) was the dominant indicator for Task 1 (mean |SHAP| = 0.439) and Task 2 (mean |SHAP| = 0.803), while the Pure Necrotic-Rich Zone (N-only) was the dominant indicator for Task 3 (mean |SHAP| = 1.967). In exploratory TCGA association analyses, the Pure Tumor-Rich Zone (T-only) exhibited a positive correlation (ρ = 0.706, p < 0.001; T-only is a feature used to derive this model-estimated RCB-like score), whereas the Lymphocyte-Infiltrated Necrotic Zone (N+L) showed a negative correlation (ρ = −0.407, p < 0.001) with the model-estimated RCB-like score, linking tumor-rich zones to immunosuppression and lymphocyte-infiltrated necrotic zones to immune activation. Conclusions: Our spatial pathological features effectively estimate RCB, with T+N and N-only as the predominant SHAP-identified indicators across the three tasks. Exploratory analyses further suggest that tumor-rich and lymphocyte-infiltrated necrotic zones correlate with opposing immune phenotypes, supporting personalized breast cancer management.

4 August 2026 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
XXXiaoyan Xu
Xiaoyan Xu
JWJianjun Wang
Jianjun Wang
XWXuan Wang
Xuan Wang
XXXianwei Xu
Xianwei Xu
JZJizhi Zhao
Jizhi Zhao
LYLiu Yang
Liu Yang